ReviewHormones (Athens, Greece)2026
Reproduction and fertility issues in women with congenital adrenal hyperplasia: pathophysiology, management, and recent clinical advances.
Review in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital adrenal hyperplasia (CAH), commonly caused by 21-hydroxylase deficiency (21-OHD), is an autosomal recessive disorder of adrenal steroidogenesis with significant implications for reproductive health. This review examines the pathophysiological mechanisms, fertility outcomes, and management strategies pertaining to reproductive function in women with classical and non-classical (NC) CAH. Fertility is generally reduced in women with classical CAH compared to the general population, owing to a combination of anatomical alterations from prenatal androgen exposure and reconstructive surgery, hypothalamic-pituitary-ovarian (HPO) axis dysregulation driven by excess adrenal androgens and progesterone, anovulation, and psychosexual factors, including altered gender-related behaviour and reduced reproductive intent. In NC CAH, fertility is only mildly impaired and most women can conceive; however, miscarriage rates are substantially higher in the absence of treatment. Optimised glucocorticoid replacement therapy is the cornerstone of management, restoring ovulatory cycles and improving conception rates in both phenotypes by suppressing adrenal androgen and progesterone excess. When ovulation fails to occur, induction with clomiphene citrate or gonadotropins may be employed; in vitro fertilisation with preimplantation genetic testing represents an option for refractory cases at high genetic risk. Pregnancy in CAH requires careful obstetric monitoring, glucocorticoid dose adjustment, and stress-dose coverage during labour. Prenatal treatment with dexamethasone to prevent virilisation of possibly affected female foetuses remains a subject of ongoing ethical and clinical debate. A multidisciplinary approach-encompassing endocrinology, reproductive medicine, surgery, and psychological support-is essential for optimising reproductive outcomes and quality of life in women with CAH.
Indexed as
Identifiers
42443698What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.